Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 27, 2014The Egyptian Heart JournalOpen Access

Atorvastatin 40 mg/day added to standard therapy for 6 weeks significantly improved cardiac function and reduced inflammatory and oxidative markers compared to standard therapy alone.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does atorvastatin improve cardiac function and biomarkers in patients with chronic heart failure (LVEF <45%) and in rat models?

Population

40 patients with chronic heart failure and LV-EF <45%, and 40 rats (doxorubicin-induced CHF model).

Comparison

Atorvastatin added to standard anti-failure… vs Standard anti-failure treatment alone; saline…

Design

RCT, Randomized

Follow-up

6 weeks (patients), 4 weeks (rats)

Key result

Atorvastatin 40 mg/day added to standard therapy for 6 weeks significantly improved cardiac function and reduced inflammatory and oxidative markers compared to standard therapy alone.

Authors

IEIbrahim ElmadbouhMMMagda MansourMNMohamed Nabeh

Discussion

Loading...

Member takes

Overview

May improve function in HFrEF; hypothesis-generating and requires randomized confirmation before practice change.

Study Design

Type

RCT (n=40)

Randomization

randomized

Structured PICO

Does atorvastatin improve cardiac function and biomarkers in patients with chronic heart failure (LVEF <45%) and in rat models?

P
Population
40 patients with chronic heart failure and LV-EF <45% randomized to standard therapy with or without atorvastatin for 6 weeks.
I
Intervention
Atorvastatin (40 mg/day for 6 weeks in patients; 10 mg/kg orally for 4 weeks in rats) added to standard anti-failure treatment or doxorubicin.
C
Comparator
Standard anti-failure treatment alone (patients); saline, doxorubicin alone, or digoxin-doxorubicin (rats).
O
Outcome
Cardiac function (LV-EF%, LV-FS%, E/A velocity ratio, LV-EDD, LV-ESD), lipid profiles, hs-CRP, cTnT, and MDA at 6 weeks (patients) and 4 weeks (rats).surrogate

Cite This Study

Elmadbouh et al. (2014) conducted an RCT in chronic non-ischemic heart failure (n=40). Atorvastatin vs. standard anti-failure treatment alone was evaluated on cardiac function and remodeling. Atorvastatin 40 mg/day added to standard therapy for 6 weeks significantly improved cardiac function and reduced inflammatory and oxidative markers compared to standard therapy alone.

synapsesocial.com/papers/6a21436ca2a97f3a085ae046https://doi.org/10.1016/j.ehj.2014.11.003
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Atorvastatin Improves Doxorubicin-Induced Cardiac Dysfunction by Modulating Hsp70, Akt, and MAPK Signaling Pathways2018 · 27 citations
  2. 2Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats2014 · 57 citations
  3. 3Treatment with atorvastatin is associated with a better prognosis in chronic heart failure with systolic dysfunction: results from The Daunia Heart Failure Registry2013 · 14 citations
  4. 4Atorvastatin Inhibits Myocardial Cell Apoptosis in a Rat Model with Post-myocardial Infarction Heart Failure by Downregulating ER Stress Response2011 · 101 citations
  5. 5Rosuvastatin Added to Standard Heart Failure Therapy Improves Cardiac Remodelling in Heart Failure Rats with Preserved Ejection Fraction2010 · 39 citations